Biogen Inc. (BIIB) Stock

Biogen Inc. (BIIB) is a Healthcare stock trading at $196.52 (as of 2026-06-18), with a market capitalization of $27.88B and a trailing P/E of 21.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biogen Inc. develops, manufactures, and commercializes therapies for neurological and other diseases, including treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease, along with medicines for conditions such as plaque psoriasis and certain cancers and autoimmune disorders. Its portfolio includes products and biosimilar medicines, with sales primarily in the U.S. and international markets.

Valuation — source: SEC EDGAR (first-party)
Price$196.52
Market Cap$27.88B
P/E Ratio21.5
EV / EBITDA13.4
Price / Book1.58
Price / Sales2.97
DCF Value (model)$171.74
DCF Upside vs Price-12.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$9.89B
Net Margin13.1%
Return on Equity7.4%
Debt / Equity0.34
Current Ratio3.06
Revenue Growth (YoY)1.9%
EPS Growth (YoY)31.5%
FCF Growth (YoY)167.5%
Financial Health — source: SEC EDGAR
Altman Z-Score3.26 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E21.5
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector2.6%
vs Industry24.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($3.07B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOChristopher A. Viehbacher
Employees7,605
CountryUS
IPO Date1991-09-17

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Amgen Inc. (AMGN)
  • Gilead Sciences, Inc. (GILD)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Incyte Corporation (INCY)
  • Neurocrine Biosciences, Inc. (NBIX)
  • Moderna, Inc. (MRNA)
BIIB earnings history · BIIB institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.